en · de · es · pt
peptide-index.peptides5388.com › Wiki › Background And Mechanism Of Sr9009 — Research Overview

Background And Mechanism Of Sr9009 — Research Overview

By Editorial Desk · published 2026-01-30 · last reviewed 2026-03-12 · Wiki

research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-03-12. Anything still debated is marked as such rather than presented as settled.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Related pages on this site

Background and Receptor Pharmacology

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Supporting material

== Environment == Dumping plastic waste: Thailand ranked sixth of 192 nations with ocean shorelines (1=worst, 192=best). Based on 2010 data, Thailand is estimated to have contributed 1.03 million tonnes of plastic waste to the ocean. The 10 biggest marine polluters (by millions of tonnes of plastic waste dumped in the ocean each year) are: China 8.8; Indonesia 3.2; The Philippines 1.9; Vietnam 1.8; Sri Lanka 1.6; Thailand 1.0; Egypt 1.0; Nigeria 0.9; Malaysia 0.9; and Bangladesh 0.8 Environmental Performance Index 2016: Thailand was ranked 91 of 180 nations (1=best, 180=worst) for its performance on environmental issues. Other ASEAN nations were ranked: Singapore, 14; Malaysia, 63; Philippines, 66; Brunei, 98; Indonesia, 107; Vietnam, 131; Cambodia, 146; Laos, 148; and Myanmmar, 153. Environmental Sustainability Index 2005: Ranked 73 of 146 countries. Fish species, threatened: Of 215 nations, Thailand ranked 12 (1=worst, 215=best) in fish species at risk (96 species) in 2014. ASEAN member-states ranked from number five (Indonesia) to 175 (Brunei). Mammal species, threatened: Of 214 countries studied, Thailand ranks ninth (1=worst, 214=best) in the world in the number of mammal species (55 species) under threat. ASEAN nations fared poorly in this study: Indonesia was number one on the world list with 184 species under threat. The remaining ASEAN nations were ranked: Malaysia, 7; Vietnam, 12; Myanmar, 14; Laos, 15; The Philippines, 19; Cambodia, 20; Brunei, 25; Singapore, 93, of 214 countries.

Reported risk factors include female sex, obesity, elevated calcium-phosphate product, medications such as warfarin, vitamin D derivatives (e.g. calcitriol, calcium-based binders, or systemic steroids), protein C or S deficiency, low blood albumin levels, and diabetes mellitus. Patients who require or have undergone any type of vascular procedures are also at increased risk for poor outcomes.

=== Odor === Kimchi is known for its strong, spicy, flavors and odors, although milder varieties exist. Variations in the fermentation process cause the final product to be highly variable in terms of quality and flavor. The strong odor is especially tied to the sulfur compounds from garlic and ginger of kimchi, which can be less appealing to non-Koreans. Thus, scientists are experimenting with the types of bacteria used in its production to minimize the odor to increase the appeal to international markets. These efforts are not universally appreciated by lovers of kimchi, as the flavor is affected in the process, and some see that "South Korea's narrative about its own culinary staple" is being manipulated to suit the foreigners' tastes.

Protein–protein interactions (PPIs) are physical contacts of high specificity established between two or more protein molecules as a result of biochemical events steered by interactions that include electrostatic forces, hydrogen bonding and the hydrophobic effect. Many are physical contacts with molecular associations between chains that occur in a cell or in a living organism in a specific biomolecular context. Proteins rarely act alone as their functions tend to be regulated. Many molecular processes within a cell are carried out by molecular machines that are built from numerous protein components organized by their PPIs. These physiological interactions make up the so-called interactomics of the organism, while aberrant PPIs are the basis of multiple aggregation-related diseases, such as Creutzfeldt–Jakob and Alzheimer's diseases. PPIs have been studied with many methods and from different perspectives: biochemistry, quantum chemistry, molecular dynamics, signal transduction, among others. All this information enables the creation of large protein interaction networks – similar to metabolic or genetic/epigenetic networks – that empower the current knowledge on biochemical cascades and molecular etiology of disease, as well as the discovery of putative protein targets of therapeutic interest.

Sources: en.wikipedia.org

Supporting material

== Binding change mechanism == The binding change mechanism, proposed by Paul Boyer and John E. Walker, who were awarded the Nobel Prize in Chemistry in 1997, suggests that ATP synthesis is linked to a conformational change in ATP synthase. This change is triggered by the rotation of the gamma subunit. ATP synthesis can be achieved through several mechanisms. The first mechanism postulates that the free energy of the proton gradient is utilized to alter the conformation of polypeptide molecules in the ATP synthesis active centers. The second mechanism suggests that the change in the conformational state is also produced by the transformation of mechanical energy into chemical energy using biological mechanoemission, a process in which energy or particles (e.g., photons or ions) are emitted from a mitochondrion when it is mechanically stimulated.

These are known as 'targeted primary health care outlet'—as these outlets primarily target people who inject drugs and/or 'low-threshold health care outlet'—as these reduce common barriers clients often face when they try to access health care from the conventional health care outlets. For accessing sterile injecting equipment clients frequently visit NSP outlets, and for receiving pharmacotherapy (e.g. methadone, buprenorphine) they visit OST clinics; these frequent visits are used opportunistically to offer much needed health care. These targeted outlets have the potential to mitigate clients' perceived barriers to access to healthcare delivered in traditional settings. The provision of accessible, acceptable and opportunistic services which are responsive to the needs of this population is valuable, facilitating a reduced reliance on inappropriate and cost-ineffective emergency department care.

== In bacteria == All bacteria use proteolipids, sometimes confusingly referred to as bacterial lipoproteins, in their cell membrane. A common modification consists of N-acyl- and S‑diacylglycerol attached to an N-terminal cystine residue. Braun's lipoprotein, found in gram-negative bacteria, is a representative of this group. In addition, Mycobacterium O-mycolate proteins destined for the outer membrane. The plant chloroplast is capable of many of the same modifications that bacteria perform to proteolipids. One database for such N-Acyl Diacyl Glycerylated cell wall proteolipids is DOLOP. Pathogenic spirochetes, including Borrelia burgdorferi and Treponema pallidum, use their proteolipid adhesins to stick to victim cells. These proteins are also potent antigens, and are in fact the main immunogens of these two species. Proteolipids include bacterial antibiotics that are not synthesised in the ribosome. Products of nonribosomal peptide synthase may also involve a peptide structure linked to lipids. These are usually referred to as "lipopeptides". Bacterial "lipoproteins" and "lipopeptides" (LP) are potent inducers of sepsis, second only to lipopolysaccharide (LPS) in its ability to cause an inflammation response. While LPS is detected by the toll-like receptor TLR4, LPs are detected by TLR2.

Sources: en.wikipedia.org

Notes from published material

The British troops had antiquated tactics—and in some cases antiquated weapons—against the mobile Boer forces with the destructive fire of their modern Mausers, the latest Krupp field guns and their novel tactics. On 7 December, a raid at Enslin Station further highlighted British weaknesses, notably their supply line, which was vulnerable to guerrilla attacks. The middle of December was disastrous for the British. In a period known as Black Week (10–15 December 1899), the British suffered defeats on three fronts. On 10 December, General Gatacre tried to recapture Stormberg railway junction about 80 kilometres (50 mi) south of the Orange River. Gatacre's attack was marked by administrative and tactical blunders and the Battle of Stormberg ended in a British defeat, with 135 killed and wounded and two guns and over 600 troops captured. At the Battle of Magersfontein on 11 December, Methuen's 14,000 British troops attempted to capture a Boer position in a dawn attack to relieve Kimberley. This too turned into a disaster when the Highland Brigade became pinned down by accurate Boer fire. After suffering from intense heat and thirst for nine hours, they eventually broke in ill-disciplined retreat. The Boer commanders, Koos de la Rey and Cronjé, had ordered trenches to be dug in an unconventional place to fool the British and give their riflemen a greater firing range. The plan worked, and this tactic helped to write the doctrine of the supremacy of the defensive position, using modern small arms and trench fortifications.

== Discovery == The discovery of hepatalin action was published in 1996 by a team led by W. Wayne Lautt from the University of Manitoba in Winnipeg, Manitoba, Canada. The many roles of the hepatic nerves had been studied for years with Lautt proposing in 1979 that hepatic parasympathetic nerve dysfunction could result in type 2 diabetes. The action of hepatalin was not seen until 1991 when an experiment was conducted to determine if insulin in the blood perfusing the brain could activate the nerves in the liver. It did not, but the response to an injection of a pulse of insulin either to the brain or systemically, was decreased by hepatic surgical denervation. Further studies showed that denervation of the liver reduced the response to insulin in the hindlimbs but had no effect on the liver.

== Spark source mass spectrometry (SSMS) == The rf spark source creates ions with a wide energy spread (2-3 kV), which necessitates a double focusing mass analyzer. Mass analyzers are typically Mattauch-Herzog geometry, which achieve velocity and directional focusing onto a plane with either photosensitive plates for ion detection or linear channeltron detector arrays. SSMS has several unique features that make it a useful technique for various applications. Merits of SSMS include high sensitivity with detection limits in the ppb range, simultaneous detection of all elements in a sample, and simple sample preparation. However, the rf spark ion current is discontinuous and erratic, which results in fair resolution and accuracy when standards are not implemented. Other drawbacks include expensive equipment, long analysis time, and the need for highly trained personnel to analyze the spectrum.

The People's Party formally confirmed its support for Bhumjaithai leader Anutin Charnvirakul to become prime minister. The agreement between the two parties was on the condition that Anutin dissolve the House within four months, Bhumjaithai must maintain a minority coalition, and must also initiate the process of amending the 2017 constitution and hold a referendum if required. Acting prime minister Phumtham Wechayachai's attempt to dissolve the House was rejected over concerns about whether an acting prime minister had the powers to do so. Anutin was elected prime minister on 5 September 2025 and was formally sworn two days later. In the three months prior to the early dissolution, he signed the Kuala Lumpur Peace Accord on 26 October, which led to an uneasy and unstable peace agreement until military engagements and re-escalation restarted on 7 December. His government was criticised for its response to online scam networks, and severe flooding in Songkhla province in the wake of Cyclone Senyar and a controversial 2025 SEA Games made negative reception. Amid rumours of an early dissolution, the House was formally dissolved on 12 December before a vote of no-confidence by the People's Party could go through.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

Network